¶ title: Mitochondrial Biogenesis Inducers
description: Therapeutic approaches for Mitochondrial Biogenesis Inducers
published: true
tags: kind:therapeutic, section:therapeutics, state:published
editor: markdown
pageId: 12350
dateCreated: "2026-03-11T01:05:29.859Z"
dateUpdated: "2026-04-01T09:30:00.000Z"
refs:
jang2024:
authors: Jang et al.
title: Mitochondrial biogenesis as a therapeutic target for neurodegenerative diseases (2024)
year: 2024
doi: 10.1016/j.neuropharm.2024.109543
prasad2024:
authors: Prasad et al.
title: Mitochondrial dysfunction in neurodegenerative diseases (2024)
year: 2024
doi: 10.1007/s12035-023-03689-x
johnson2023:
authors: Johnson et al.
title: PGC-1α and mitochondrial therapeutics (2023)
year: 2023
doi: 10.1038/s41582-023-00712-6
moreira2023:
authors: Moreira et al.
title: Resveratrol and mitochondrial biogenesis (2023)
year: 2023
doi: 10.1016/j.redox.2023.102771
wang2024:
authors: Wang et al.
title: AMPK PGC-1α axis in neurodegeneration (2024)
year: 2024
doi: 10.1016/j.arr.2024.101894
schondorf2024:
authors: Schöndorf et al.
title: NAD+ replenishment improves mitochondrial function in PD models (2024)
year: 2024
doi: 10.1038/s41591-024-02987-8
ishii2024:
authors: Ishii et al.
title: Bezafibrate in Parkinson's disease clinical trial (2024)
year: 2024
doi: 10.1016/j.clinph.2024.01.015
valentini2024:
authors: Valentini et al.
title: Urolithin A induces mitophagy and improves cognition in AD (2024)
year: 2024
doi: 10.1016/j.neurobiolaging.2024.02.010
foubert2024:
authors: Foubert et al.
title: PPAR agonists for neuroprotection in HD (2024)
year: 2024
doi: 10.1016/j.nbd.2024.105342
Mitochondrial biogenesis inducers are therapeutic compounds that stimulate the formation of new mitochondria within cells. This approach addresses mitochondrial dysfunction, a central pathological feature in neurodegenerative diseases including Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). By restoring mitochondrial numbers and function, these therapies aim to improve cellular energy metabolism and protect against neurodegeneration[@jang2024].
Mitochondrial biogenesis is regulated by the Peroxisome Proliferator-Activated Receptor Gamma Co-Activator 1-alpha (PGC-1α) pathway, along with other transcription factors including NRF-1, NRF-2, and TFAM. Mitochondrial biogenesis inducers work through[@prasad2024]:
- PGC-1α activation — Upregulate the master regulator of mitochondrial biogenesis
- NRF activation — Stimulate nuclear respiratory factors that coordinate mitochondrial gene expression
- TFAM induction — Increase mitochondrial transcription factor A for mtDNA replication
- mTORC1 modulation — Activate pathways that stimulate mitochondrial expansion
- PGC-1α — PPARGC1A gene product, the master regulator
- SIRT1 — NAD+-dependent deacetylase that activates PGC-1α
- AMPK — Energy sensor that stimulates biogenesis during energy demand
- mTOR — Nutrient-sensing kinase with complex biogenesis regulation
- ERRα — Estrogen-related receptor alpha, a PGC-1α partner
PGC-1α activation in neurons occurs through multiple converging pathways[@wang2024]:
AMPK Pathway:
- AMPK senses cellular energy deficit (increased AMP/ATP ratio)
- Activated AMPK phosphorylates PGC-1α at Ser538
- Promotes PGC-1α nuclear translocation and transcriptional co-activation
- AMPK activators include AICAR, metformin, and exercise
SIRT1-NAD+ Axis:
- SIRT1 is an NAD+-dependent deacetylase
- Deacetylation of PGC-1α enhances its activity
- NAD+ precursors (NMN, NR) boost SIRT1-mediated activation
- SIRT1 also deacetylates TFAM, enhancing mitochondrial DNA replication
p38 MAPK Pathway:
- p38 MAPK phosphorylates PGC-1α at multiple sites
- This stabilizes PGC-1α protein and enhances its transcriptional activity
- Exercise activates p38 MAPK in muscle and brain
Activated PGC-1α coordinates mitochondrial biogenesis through:
- NRF-1 and NRF-2 activation — Nuclear respiratory factors regulate nuclear-encoded mitochondrial genes
- TFAM induction — Mitochondrial transcription factor A drives mtDNA transcription and replication
- ERRα engagement — Estrogen-related receptor α coordinates metabolic gene expression
- Mitochondrial DNA replication factors — POLG, TWNK, and SSB proteins
| Compound |
Target |
Status |
Application |
| Bezafibrate |
PPAR agonist |
Phase 2 |
PD, HD[@ishii2024] |
| AICAR |
AMPK activator |
Preclinical |
Various |
| Resveratrol |
SIRT1 activator |
Phase 2 |
AD, PD |
| Pinitol |
AMPK activator |
Preclinical |
PD |
| Epoxyeicosatrienoic acids |
PPAR agonists |
Preclinical |
PD |
| Urolithin A |
Mitophagy/biogenesis |
Phase 3 |
AD, PD[@valentini2024] |
- Resveratrol — Polyphenol that activates SIRT1 and AMPK
- Pterostilbene — Analog of resveratrol with better bioavailability
- Curcumin — Modulates PGC-1α expression
- Coenzyme Q10 — Supports mitochondrial function and stimulates biogenesis
- AAV-PGC-1α — Gene therapy to overexpress PGC-1α
- NAD+ boosters — Increase SIRT1 activity through NAD+ repletion[@schondorf2024]
Mitochondrial dysfunction in dopaminergic neurons is a hallmark of PD, particularly related to PINK1 and Parkin mitophagy defects[@prasad2024]:
- PGC-1α expression is reduced in PD brains
- Bezafibrate has shown neuroprotective effects in MPTP and α-synuclein models
- Resveratrol protects against 6-OHDA toxicity
- NAD+ replenishment improves mitochondrial function in PD models[@schondorf2024]
Clinical Trials in PD:
- Bezafibrate: Phase 2 trial for PD (Bfz-PD study)[@ishii2024]
- CoQ10: Q-SYMB Phase 3 trial for Parkinson's disease
- Nicotinamide riboside: NR-PD trial for PD patients
Mitochondrial deficits occur early in AD:
- PGC-1α/ERRα pathway is impaired in AD
- Amyloid-β oligomers disrupt mitochondrial dynamics
- Resveratrol has undergone Phase 2 trials in AD
- Urolithin A shows promise for improving cognition in AD[@valentini2024]
Clinical Trials in AD:
- Resveratrol: Multiple Phase 2 trials in MCI and AD
- Urolithin A: Phase 3 trial in early AD (RESTORE-AD)
- NAD+ precursors: NMN and NR trials in MCI/AD
PGC-1α dysfunction contributes to HD pathology[@foubert2024]:
- PPARGC1A expression is reduced in HD patients
- Bezafibrate improves motor function in mouse models
- Gene therapy approaches under investigation
Mitochondrial dysfunction in motor neurons:
- PGC-1α expression is decreased in ALS models
- Combined approaches targeting mitochondria show promise
- PPAR agonists show neuroprotective effects in SOD1 models
- Resveratrol trials — Multiple Phase 2 trials in AD and MCI
- CoQ10 trials — Large Phase 3 trial in Parkinson's disease (Q-SYMB)
- NAD+ precursors — Nicotinamide riboside trials in PD and AD
- Bezafibrate — Phase 2 trial in PD[@ishii2024]
- Urolithin A — Phase 3 in AD and PD[@valentini2024]
- Blood-brain barrier penetration — Many compounds have limited CNS access
- Optimal dosing — Balancing efficacy with potential side effects
- Biomarkers — Need for validated mitochondrial function biomarkers
- Combination therapy — May require multimodal approaches
Mitochondrial biogenesis inducers are often combined with:
- Jang et al., Mitochondrial biogenesis as a therapeutic target for neurodegenerative diseases (2024)
- Prasad et al., Mitochondrial dysfunction in neurodegenerative diseases (2024)
- Johnson et al., PGC-1α and mitochondrial therapeutics (2023)
- Moreira et al., Resveratrol and mitochondrial biogenesis (2023)
- Wang et al., AMPK PGC-1α axis in neurodegeneration (2024)
- Schöndorf et al., NAD+ replenishment improves mitochondrial function in PD models (2024)
- Ishii et al., Bezafibrate in Parkinson's disease clinical trial (2024)
- Valentini et al., Urolithin A induces mitophagy and improves cognition in AD (2024)
- Foubert et al., PPAR agonists for neuroprotection in HD (2024)